Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near the end of life. We evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Ravi B., Galsky, Matthew D., Gyawali, Bishal, Riaz, Fauzia, Kaufmann, Tara L., Cohen, Aaron B., Adamson, Blythe J.S., Gross, Cary P., Meropol, Neal J., Mamtani, Ronac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656487/
https://www.ncbi.nlm.nih.gov/pubmed/30944183
http://dx.doi.org/10.1634/theoncologist.2019-0039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656487/
https://www.ncbi.nlm.nih.gov/pubmed/30944183
http://dx.doi.org/10.1634/theoncologist.2019-0039

Ejemplares similares